Wall Street analysts forecast that Allena Pharmaceuticals Inc (NASDAQ:ALNA) will report earnings of ($0.54) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Allena Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.40) and the lowest estimate coming in at ($0.58). Allena Pharmaceuticals posted earnings per share of ($0.46) during the same quarter last year, which indicates a negative year over year growth rate of 17.4%. The business is expected to issue its next quarterly earnings report on Thursday, March 5th.
Zacks’ earnings per share averages are an average based on a survey of research firms that follow Allena Pharmaceuticals.
Allena Pharmaceuticals (NASDAQ:ALNA) last posted its earnings results on Wednesday, November 13th. The company reported ($0.57) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.49) by ($0.08).
Several analysts have weighed in on the stock. Cowen reissued a “buy” rating on shares of Allena Pharmaceuticals in a research note on Thursday, November 14th. Wedbush restated a “buy” rating and set a $26.00 price objective on shares of Allena Pharmaceuticals in a research report on Thursday, December 5th. Credit Suisse Group downgraded shares of Allena Pharmaceuticals from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $7.00 to $4.00 in a research report on Friday, November 8th. Finally, Zacks Investment Research raised shares of Allena Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, November 12th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $17.96.
A number of institutional investors and hedge funds have recently made changes to their positions in ALNA. Wedbush Securities Inc. bought a new stake in Allena Pharmaceuticals during the 2nd quarter valued at about $63,000. Jacobs Levy Equity Management Inc. grew its position in Allena Pharmaceuticals by 17.0% during the 2nd quarter. Jacobs Levy Equity Management Inc. now owns 41,587 shares of the company’s stock worth $169,000 after purchasing an additional 6,030 shares during the last quarter. Paloma Partners Management Co acquired a new stake in Allena Pharmaceuticals during the 2nd quarter valued at approximately $212,000. Jane Street Group LLC acquired a new position in shares of Allena Pharmaceuticals in the 2nd quarter valued at $116,000. Finally, Susquehanna International Group LLP acquired a new position in Allena Pharmaceuticals during the second quarter worth $137,000. Institutional investors own 64.60% of the company’s stock.
Shares of ALNA traded up $0.06 during mid-day trading on Friday, reaching $2.32. 321,514 shares of the stock traded hands, compared to its average volume of 346,816. The firm has a fifty day moving average price of $3.02 and a 200 day moving average price of $4.01. The company has a market cap of $45.29 million, a price-to-earnings ratio of -1.35 and a beta of 1.62. The company has a current ratio of 3.96, a quick ratio of 3.96 and a debt-to-equity ratio of 0.28. Allena Pharmaceuticals has a 1 year low of $1.55 and a 1 year high of $9.60.
Allena Pharmaceuticals Company Profile
Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.
Further Reading: What is an investor looking for in an SEC filing?
Get a free copy of the Zacks research report on Allena Pharmaceuticals (ALNA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.